Although treatment with a proteasome inhibitor, CUL-4A activator inhibitor, or EZH2 inhibitor led to readily detectable steady-state levels of DLC1 protein, this single-agent treatment by itself had a limited impact on reducing RhoA-GTP levels or inhibiting anchorage-independent growth and tumor growth. Here, EZH2 is linked to neoplasm.